Search

Your search keyword '"Fiori, G."' showing total 32 results
Start Over Author "Fiori, G." Publisher bmj
32 results on '"Fiori, G."'

4. POS1495-HPR THE EXPERIENCE OF A RHEUMATOLOGY UNIT DURING THE COVID19 LOCKDOWN: TELEMEDICINE ALLOWS A SAFE FOLLOW UP OF PATIENTS WITH RHEUMATIC DISEASES

Author

El Aoufy, K., primary, Melis, M. R., additional, Bellando Randone, S., additional, Blagojevic, J., additional, Bartoli, F., additional, Fiori, G., additional, Nacci, F., additional, Conforti, M. L., additional, Cometi, L., additional, Bruni, C., additional, Moggi Pignone, A., additional, Rasero, L., additional, Guiducci, S., additional, and Matucci-Cerinic, M., additional

Published
2021
Full Text
View/download PDF

7. THU0360 EFFICACY OF A SELF-TREATMENT PROTOCOL FOR FACE AND TEMPOROMANDIBULAR JOINTS REHABILITATION IN SYSTEMIC SCLEROSIS (SSC)

Author

Passalacqua, M., primary, Foggi, C., additional, Mauro, N., additional, Tofani, L., additional, Guiducci, S., additional, Bruni, C., additional, Lepri, G., additional, Blagojevic, J., additional, El Aoufy, K., additional, Fiori, G., additional, Bartoli, F., additional, Maddali Bongi, S., additional, Mitola, M., additional, Gizduloch, M., additional, Matucci-Cerinic, M., additional, and Bellando Randone, S., additional

Published
2020
Full Text
View/download PDF

8. AB0281 SAFETY AND RETENTION RATE AFTER SWITCHING FROM ETANERCEPT ORIGINATOR (ETN) TO ETANERCEPT BIOSIMILAR (SB4) IN INFLAMMATORY JOINT DISEASES: DATA FROM REAL LIFE.

Author

Bruni, C., primary, Gentileschi, S., additional, Capassoni, M., additional, Pacini, G., additional, Bardelli, M., additional, Baldi, C., additional, Tofani, L., additional, Cometi, L., additional, Nacci, F., additional, Bartoli, F., additional, Fiori, G., additional, Cantarini, L., additional, Guiducci, S., additional, Frediani, B., additional, and Matucci-Cerinic, M., additional

Published
2020
Full Text
View/download PDF

15. AB0466 Quantiferon (QFT) identifies latent tuberculosis (LTB) but does not help the evaluation of the efficacy of prophylaxis in inflammatory arthritides

Author

Peruzzi, F., primary, Bartalesi, F., additional, Attala, L., additional, Cavallo, A., additional, Fiori, G., additional, Maddali-Bongi, S., additional, Bruni, C., additional, Nacci, F., additional, Bartoli, F., additional, Cappelli, S., additional, Denaro, V., additional, Bartoloni, A., additional, and Matucci-Cerinic, M., additional

Published
2013
Full Text
View/download PDF

20. Bone marrow-derived mesenchymal stem cells from early diffuse systemic sclerosis exhibit a paracrine machinery and stimulate angiogenesis in vitro

Author

Guiducci, S., primary, Manetti, M., additional, Romano, E., additional, Mazzanti, B., additional, Ceccarelli, C., additional, Dal Pozzo, S., additional, Milia, A. F., additional, Bellando-Randone, S., additional, Fiori, G., additional, Conforti, M. L., additional, Saccardi, R., additional, Ibba-Manneschi, L., additional, and Matucci-Cerinic, M., additional

Published
2011
Full Text
View/download PDF

24. Reduced circulating levels of angiotensin-(1 7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control

Author

Pignone, A., primary, Rosso, A. D., additional, Brosnihan, K B., additional, Perfetto, F., additional, Livi, R., additional, Fiori, G., additional, Guiducci, S., additional, Cinelli, M., additional, Rogai, V., additional, Tempestini, A., additional, Bartoli, F., additional, Generini, S., additional, Ferrario, C. M, additional, and Cerinic, M. M., additional

Published
2007
Full Text
View/download PDF

30. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study.

Author

Elhai M, Meunier M, Matucci-Cerinic M, Maurer B, Riemekasten G, Leturcq T, Pellerito R, Von Mühlen CA, Vacca A, Airo P, Bartoli F, Fiori G, Bokarewa M, Riccieri V, Becker M, Avouac J, Müller-Ladner U, Distler O, and Allanore Y

Subjects
Abatacept, Adult, Arthritis etiology, Female, Humans, Male, Middle Aged, Muscular Diseases etiology, Prospective Studies, Treatment Outcome, Antibodies, Monoclonal, Humanized therapeutic use, Antirheumatic Agents therapeutic use, Arthritis drug therapy, Immunoconjugates therapeutic use, Muscular Diseases drug therapy, Scleroderma, Systemic complications
Abstract

Objective: To evaluate the safety and effectiveness of tocilizumab and abatacept in systemic sclerosis (SSc)-polyarthritis or SSc-myopathy., Methods: 20 patients with SSc with refractory polyarthritis and seven with refractory myopathy from the EUSTAR (EULAR Scleroderma Trials and Research) network were included: 15 patients received tocilizumab and 12 patients abatacept. All patients with SSc-myopathy received abatacept. Clinical and biological assessments were made at the start of treatment and at the last infusion., Results: After 5 months, tocilizumab induced a significant improvement in the 28-joint count Disease Activity Score and its components, with 10/15 patients achieving a EULAR good response. Treatment was stopped in two patients because of inefficacy. After 11 months' treatment of patients with abatacept, joint parameters improved significantly, with 6/11 patients fulfilling EULAR good-response criteria. Abatacept did not improve muscle outcome measures in SSc-myopathy. No significant change was seen for skin or lung fibrosis in the different groups. Both treatments were well tolerated., Conclusions: In this observational study, tocilizumab and abatacept appeared to be safe and effective on joints, in patients with refractory SSc. No trend for any change of fibrotic lesions was seen but this may relate to the exposure time and inclusion criteria. Larger studies with longer follow-up are warranted to further determine the safety and effectiveness of these drugs in SSc.

Published
2013
Full Text
View/download PDF

31. Autologous stem cell transplantation improves microcirculation in systemic sclerosis.

Author

Miniati I, Guiducci S, Conforti ML, Rogai V, Fiori G, Cinelli M, Saccardi R, Guidi S, Bosi A, Tyndall A, and Matucci-Cerinic M

Subjects
Adult, Cyclophosphamide therapeutic use, Drug Administration Schedule, Female, Humans, Immunosuppressive Agents therapeutic use, Male, Microscopic Angioscopy methods, Middle Aged, Nails blood supply, Prospective Studies, Regional Blood Flow, Statistics, Nonparametric, Transplantation, Autologous, Video Recording, Hematopoietic Stem Cell Transplantation, Microcirculation, Scleroderma, Diffuse drug therapy, Scleroderma, Diffuse physiopathology, Scleroderma, Diffuse surgery
Abstract

Background: In systemic sclerosis (SSc) reduced capillary density decreases blood flow and leads to tissue ischaemia and fingertip ulcers. Nail fold videocapillaroscopy (NVC) is a diagnostic and follow-up parameter useful to evaluate the severity, activity and the stage of SSc microvascular damage. Autologous haemopoietic stem cell transplantation (HSCT) is a new treatment for patients with severe diffuse cutaneous systemic sclerosis (dcSSc) refractory to conventional therapies. We aimed to evaluate the improvement of microvasculature after HSCT using NVC., Methods: A total of 16 patients with severe dcSSc with a "late" videocapillaroscopy pattern underwent an immunesuppressive treatment: 6 were treated with HSCT and 10 with monthly pulse cyclophosphamide (CYC) 1 g for 6 months and then orally with 50 mg/day for further 6 months. NVC was performed before and after 3 months from the beginning of each treatment and then repeated every 3 months., Results: In all patients, before HSCT NVC showed large avascular areas and ramified capillaries and vascular architectural disorganisation ("late" pattern). At 3 months after HSCT, the NVC pattern changed from "late" into "active", showing frequent giant capillaries (>6/mm) and haemorrhages, absence of avascular areas and angiogenesis phenomena; 1 year after HSCT, microvascular abnormalities were still in the "active" pattern. In patients treated with CYC, no NVC modifications were observed during 24 months of follow-up and the pattern always remained "late"., Conclusions: These results indicate that HSCT with a high dose CYC regimen may foster vascular remodelling, while CYC at lower doses and with a chronic regimen does not influence the microvasculature.

Published
2009
Full Text
View/download PDF

32. Pulmonary arterial hypertension in systemic sclerosis: diagnostic pathway and therapeutic approach.

Author

Robertson L, Pignone A, Kowal-Bielecka O, Fiori G, Denton CP, and Matucci-Cerinic M

Subjects
Aged, Female, Humans, Hypertension, Pulmonary diagnosis, Hypertension, Pulmonary therapy, Lung Diseases, Interstitial complications, Lung Diseases, Interstitial diagnosis, Middle Aged, Hypertension, Pulmonary etiology, Scleroderma, Systemic complications
Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results